These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12767972)

  • 21. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ; Jones RJ
    Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Malik V; Kupfer Y; Tessler S
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14658127
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 24. Heparin and CXCL12 dimerization.
    Altundag K; Altundag O; Atik MA
    J Clin Oncol; 2005 Oct; 23(28):7248. PubMed ID: 16192624
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Huisman MV; van der Meer FJ; van Rooden CJ; Prins MH
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14645647
    [No Abstract]   [Full Text] [Related]  

  • 26. Outpatient management of anticoagulation therapy.
    du Breuil AL; Umland EM
    Am Fam Physician; 2007 Apr; 75(7):1031-42. PubMed ID: 17427618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.
    Palareti G; Legnani C; Cosmi B; Guazzaloca G; Cini M; Mattarozzi S
    J Thromb Haemost; 2005 May; 3(5):955-61. PubMed ID: 15869591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of deep venous thrombosis, including the newer agents.
    Rectenwald JE; Wakefield TW
    Dis Mon; 2005; 51(2-3):104-11. PubMed ID: 15900261
    [No Abstract]   [Full Text] [Related]  

  • 30. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal initial dose adjustment of warfarin in orthopedic patients.
    Lenzini PA; Grice GR; Milligan PE; Gatchel SK; Deych E; Eby CS; Burnett RS; Clohisy JC; Barrack RL; Gage BF
    Ann Pharmacother; 2007 Nov; 41(11):1798-804. PubMed ID: 17911206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current trends in the management of deep venous thrombosis and postthrombotic syndrome.
    Raju S; Neglen P
    J Miss State Med Assoc; 2001 Feb; 42(2):35-41. PubMed ID: 11214388
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.
    Ikhlaque N; Seshadri V; Kathula S; Baumann MA
    Am J Hematol; 2006 Jun; 81(6):420-2. PubMed ID: 16680743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism.
    Prandoni P; Lensing AW; Bagatella P; Simioni P; Girolami A
    Thromb Haemost; 1999 Jul; 82(1):158-9. PubMed ID: 10456478
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of thrombosis in the cancer patient.
    Andrea N; Ansell J
    J Support Oncol; 2003; 1(4):235-8, 240-2; discussion 239-40, 243-5. PubMed ID: 15334865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Office management of deep venous thrombosis in the elderly.
    Jacobs LG; Billett HH
    Am J Med; 2009 Oct; 122(10):904-6. PubMed ID: 19786156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation.
    Spyropoulos AC
    Dis Mon; 2005; 51(2-3):183-93. PubMed ID: 15900271
    [No Abstract]   [Full Text] [Related]  

  • 39. Central retinal venous occlusion and cerebral venous thrombosis.
    Turan TN; Biousse V; Newman NJ
    Arch Neurol; 2007 Apr; 64(4):609; author reply 609. PubMed ID: 17420329
    [No Abstract]   [Full Text] [Related]  

  • 40. [Heparin and cancer].
    Lykke J
    Ugeskr Laeger; 2006 Dec; 168(50):4397-401. PubMed ID: 17217864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.